Samus Therapeutics

Samus Therapeutics is a biopharmaceutical company dedicated to developing novel therapies targeting the capsid protein. The capsid protein is a fundamental protein complex found in a variety of diseases, including cancer and neurological disorders such as Alzheimer's disease, Parkinson's disease, and chronic traumatic encephalopathy (CTE). The company’s lead drug is PU-AD (icapamespib) for the treatment of recurrent malignant glioma.